This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Human Research Ethics Committee (University of the Witwatersrand) | |
|---|---|
| Name | Human Research Ethics Committee (University of the Witwatersrand) |
| Formation | 20th century |
| Headquarters | Johannesburg |
| Parent organization | University of the Witwatersrand |
| Region served | Gauteng |
Human Research Ethics Committee (University of the Witwatersrand) The Human Research Ethics Committee at the University of the Witwatersrand is an institutional review board that oversees ethical approval for human-subjects research conducted within the university and affiliated hospitals such as Chris Hani Baragwanath Hospital and Charlotte Maxeke Johannesburg Academic Hospital. It operates within the regulatory environment shaped by instruments like the National Health Act, 2003 (South Africa), the Helsinki Declaration, and regional frameworks associated with institutions including World Health Organization, South African Medical Research Council, and African Union. The committee interacts with researchers from faculties such as School of Clinical Medicine, Faculty of Health Sciences, and affiliated units like Wits Reproductive Health and HIV Institute.
The committee traces its origins to post-apartheid reforms and institutional consolidation at the University of the Witwatersrand alongside national legal developments including the National Health Act, 2003 (South Africa) and international documents such as the Belmont Report and the Declaration of Helsinki. During the late 20th century the committee engaged with research programs linked to institutions like Nelson Mandela School of Medicine, South African Medical Research Council, and global partners including National Institutes of Health and European Commission. Episodes in its past reflect responses to high-profile trials and inquiries involving partners like London School of Hygiene & Tropical Medicine, Harvard University, and University of Oxford.
The committee is constituted under university statutes and draws membership from disciplines represented by units such as Faculty of Health Sciences, School of Public Health, and clinical departments connected to Chris Hani Baragwanath Hospital and Helen Joseph Hospital. Membership includes clinicians from Charlotte Maxeke Johannesburg Academic Hospital, bioethicists associated with centres like Centre for Medical Ethics, legal advisers familiar with the Constitution of South Africa, and community representatives mirroring links to organizations such as Treatment Action Campaign and Health Systems Trust. The committee reports to university governance bodies including the Senate of the University of the Witwatersrand and coordinates with regulatory agencies like South African Health Products Regulatory Authority.
The committee's mandate is to ensure protection of participants in human research in line with instruments such as the Declaration of Helsinki and national statutes including the National Health Act, 2003 (South Africa). Core functions include ethical review of protocols from investigators at units like Wits Institute for Social and Economic Research, assessment of informed consent forms used in studies linked to Wits Reproductive Health and HIV Institute, monitoring adverse events in trials registered with entities like Pan African Clinical Trials Registry, and oversight of research supported by funders such as the Wellcome Trust, National Institutes of Health, and Bill & Melinda Gates Foundation.
Protocol submission procedures require documentation consistent with standards promulgated by bodies such as World Health Organization, South African Medical Research Council, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The committee operates review modalities including full-board review, expedited review, and exemptions mirroring frameworks used by Institutional Review Board systems at institutions like Harvard Medical School, University of Cape Town, and University of Oxford. It maintains processes for adverse event reporting linked to trials involving partners such as GSK and Pfizer, and for data-monitoring arrangements akin to those overseen by Data Safety Monitoring Boards in multicentre trials.
The committee enforces policies that reference the Declaration of Helsinki, the Belmont Report, national guidance from the National Health Act, 2003 (South Africa), and operational guidelines aligned with the South African Medical Research Council. Policies govern informed consent, research with vulnerable populations including cohorts comparable to studies at Wits Reproductive Health and HIV Institute and Nelson Mandela School of Medicine, biobanking standards reflecting models used by UK Biobank and ethics for genetic research paralleling guidelines from Human Genome Project stakeholders. Data protection policies take cues from instruments like the Protection of Personal Information Act, 2013 (South Africa) and international practice exemplified by General Data Protection Regulation.
The committee has adjudicated on high-profile matters involving HIV research, vaccine trials, and community-based interventions with affiliations to organizations such as Wits Reproductive Health and HIV Institute, Médecins Sans Frontières, and South African Medical Research Council. Past controversies involved debates over consent models reminiscent of disputes at Harvard University and Oxford Vaccine Group, questions about post-trial access similar to cases involving GSK and Pfizer, and scrutiny over data-sharing arrangements paralleling controversies at Wellcome Trust-funded projects. The committee’s rulings have influenced institutional policy reform at the University of the Witwatersrand and prompted engagement with provincial health departments like Gauteng Department of Health.
Training initiatives include ethics workshops for investigators from faculties such as Faculty of Health Sciences and programmes modelled after training by World Health Organization and South African Medical Research Council. Outreach engages community advisory boards and civil-society partners like Treatment Action Campaign and Health Systems Trust to inform consent processes and community engagement strategies similar to those used in multicentre trials by HIV Vaccine Trials Network. The committee collaborates with international partners including Wellcome Trust, National Institutes of Health, and European Commission to deliver capacity-building for researchers and community stakeholders.